Inhibition of West Nile virus replication in cells stably transfected with vector-based shRNA expression system

2008 ◽  
Vol 135 (2) ◽  
pp. 292-297 ◽  
Author(s):  
S.P. Ong ◽  
J.J.H. Chu ◽  
M.L. Ng
2018 ◽  
Vol 12 (10) ◽  
pp. e0006886 ◽  
Author(s):  
Agathe M. G. Colmant ◽  
Sonja Hall-Mendelin ◽  
Scott A. Ritchie ◽  
Helle Bielefeldt-Ohmann ◽  
Jessica J. Harrison ◽  
...  

2004 ◽  
Vol 78 (14) ◽  
pp. 7737-7747 ◽  
Author(s):  
Brenda L. Fredericksen ◽  
Maria Smith ◽  
Michael G. Katze ◽  
Pei-Yong Shi ◽  
Michael Gale

ABSTRACT Recent outbreaks of West Nile Virus (WNV) have been associated with an increase in morbidity and mortality in humans, birds, and many other species. We have initiated studies to define the molecular mechanisms by which a recent pathogenic isolate of WNV evades the host cell innate antiviral response. Biochemical and microarray analyses demonstrated that WNV induced the expression of beta interferon (IFN-β) and several IFN-stimulated genes late in infection of cultured human cells. The late expression of these antiviral genes was due to the delayed activation of the transcription factor IFN regulatory factor 3 (IRF-3). Despite this host response, WNV was still able to replicate efficiently. The effect of the IRF-3 pathway on WNV replication was assessed by examining virus replication and spread in cultures of wild-type or IRF-3-null mouse embryo fibroblasts. The absence of IRF-3 was marked by a significant increase in plaque size and a sustained production of infectious particles. Although the activation of the IRF-3 pathway was not sufficient to block virus replication, our results suggest that IRF-3 target genes function to constrain WNV infection and limit cell-to-cell virus spread.


2008 ◽  
Vol 135 (1) ◽  
pp. 64-71 ◽  
Author(s):  
Byron E.E. Martina ◽  
Penelopie Koraka ◽  
Petra van den Doel ◽  
Guus F. Rimmelzwaan ◽  
Bart L. Haagmans ◽  
...  

Virology ◽  
2007 ◽  
Vol 364 (1) ◽  
pp. 184-195 ◽  
Author(s):  
Shannan L. Rossi ◽  
Rafik Fayzulin ◽  
Nathan Dewsbury ◽  
Nigel Bourne ◽  
Peter W. Mason

2000 ◽  
Vol 182 (4) ◽  
pp. 1214-1217 ◽  
Author(s):  
Ingo Jordan ◽  
Thomas Briese ◽  
Nicole Fischer ◽  
Johnson Yiu‐Nam Lau ◽  
W. Ian Lipkin

2009 ◽  
Vol 16 (9) ◽  
pp. 1332-1337 ◽  
Author(s):  
Michael M. Lieberman ◽  
Vivek R. Nerurkar ◽  
Haiyan Luo ◽  
Bruce Cropp ◽  
Ricardo Carrion ◽  
...  

ABSTRACT The immunogenicity and protective efficacy of a recombinant subunit West Nile virus (WNV) vaccine was evaluated in rhesus macaques (Macaca mulatta). The vaccine consisted of a recombinant envelope (E) protein truncated at the C-terminal end, resulting in a polypeptide containing 80% of the N-terminal amino acids of the native WNV protein (WN-80E), mixed with an adjuvant (GPI-0100). WN-80E was produced in a Drosophila melanogaster expression system with high yield and purified by immunoaffinity chromatography using a monoclonal antibody specific for flavivirus E proteins. Groups of monkeys were vaccinated with formulations containing 1 or 25 μg of WN-80E antigen, and both humoral and cellular immunity were assessed after vaccination. The results demonstrated potent antibody responses to vaccination, as determined by both enzyme-linked immunosorbent assay and virus-neutralizing antibody assays. All vaccinated animals responded favorably, and there was little difference in response between animals immunized with 1 or 25 μg of WN-80E. Cellular immunity was determined by lymphocyte proliferation and cytokine production assays using peripheral blood mononuclear cells from vaccinated animals stimulated in vitro with WN-80E. Cell-mediated immune responses varied from animal to animal within each group. About half of the animals responded with lymphoproliferation, cytokine production, or both. Again, there was little difference in response between animals immunized with a 1- or 25-μg dose of WN-80E in the vaccine formulations. In a separate experiment, groups of monkeys were immunized with the WN-80E/GPI-0100 vaccine or an adjuvant-only control formulation. Animals were then challenged by inoculation of wild-type WNV, and the level of viremia in each animal was monitored daily for 10 days. The results showed that whereas all animals in the control group had detectable viremia for at least 3 days after challenge, all of the vaccinated animals were negative on all days after challenge. Thus, the WN-80E vaccine was 100% efficacious in protecting monkeys against infection with WNV.


Sign in / Sign up

Export Citation Format

Share Document